Literature DB >> 8911148

Integrin alpha 4 beta 7 mediates human eosinophil interaction with MAdCAM-1, VCAM-1 and fibronectin.

G M Walsh1, F A Symon, A L Lazarovils, A J Wardlaw.   

Abstract

We have investigated the contribution of integrin alpha 4 beta 7 to human peripheral blood eosinophil adhesive interactions. Immunofluorescence and flow cytometry demonstrated constitutive expression of alpha 4 beta 7 by eosinophils. Expression of alpha 4 beta 7 or alpha 4 beta 7 was not enhanced by eosinophil activation with platelet-activating factor (PAF). Expression of alpha 4 beta 7 was confirmed by immuno-precipitation of 125I-labeled lysates analysed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE). Approximately 20% of unstimulated eosinophils were adherent to L1-2 cells transfected with vascular cell adhesion molecule-1 (VCAM-1) cDNA, while very few resting eosinophils adhered to mouse mucosal adressin cell adhesion molecule-1 (MAdCAM-1) transfectants. Binding of unstimulated eosinophils to VCAM-1 transfectant was inhibited by HPI 2 (an antibody that blocks both alpha 4 beta 1 and alpha 4 beta 7 functions), but not Act-1, and alpha 4 beta 1 monoclonal antibody (mAb). PAF stimulation resulted in increased binding of eosinophils to MAdCAM-1 transfectants, which was inhibited by both HPI 2 and Act-1. In contrast, PAF did not enhance binding to VCAM 1 transfectants, although binding of PAE-stimulated eosinophils to VCAM-1 could be partially inhibited by Act-1. Stimulation of eosinophils with the beta 7-activating mAb TS2 16 resulted in enhanced binding of eosinophils to both VCAM-1 and MAdCAM-1 transfectants. The increased binding was largely alpha 4 beta 7-dependent. Unstimulated eosinophils bound to soluble recombinant human (rh) VCAM-1 and fibronectin (Fn), coated on 96-well plates in dose-dependent manner. Binding was inhibited by HPI-2 and 4b4, an anti-beta 1 mAb, but not by Act-1. TS2 16 treatment increased adherent cell numbers and this enhanced binding was inhibited by Act-1. We have therefore confirmed that alpha 4 beta 7 is functionally active on unstimulated eosinophils. In contrast, PAF-induced enhancement of eosinophils binding to VCAM-1 or MAdCAM-1 was alpha 4 beta 7-dependent. In addition treatment with TS2 16 resulted in a alpha 4 beta 7-dependent enhancement of eosinophil binding to VCAM-1, MAdCAM-1 and Fn. We therefore hypothesize that alpha 4 beta 7 may have an important role in eosinophil localization in diseases such as asthma and inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911148      PMCID: PMC1456673          DOI: 10.1046/j.1365-2567.1996.d01-713.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  50 in total

1.  Expression and functional significance of an activation-dependent epitope of the beta 1 integrins in chronic inflammatory diseases.

Authors:  A G Arroyo; R García-Vicuña; M Marazuela; T A Yednock; R González-Amaro; F Sánchez-Madrid
Journal:  Eur J Immunol       Date:  1995-06       Impact factor: 5.532

2.  Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity.

Authors:  A J Wardlaw; S Dunnette; G J Gleich; J V Collins; A B Kay
Journal:  Am Rev Respir Dis       Date:  1988-01

Review 3.  The dynamic regulation of integrin adhesiveness.

Authors:  M S Diamond; T A Springer
Journal:  Curr Biol       Date:  1994-06-01       Impact factor: 10.834

4.  Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen.

Authors:  A I Lazarovits; R A Moscicki; J T Kurnick; D Camerini; A K Bhan; L G Baird; M Erikson; R B Colvin
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

5.  Human eosinophils preferentially survive on tissue fibronectin compared with plasma fibronectin.

Authors:  G M Walsh; F A Symon; A J Wardlaw
Journal:  Clin Exp Allergy       Date:  1995-11       Impact factor: 5.018

6.  Augmentation of stimulated eosinophil degranulation by VLA-4 (CD49d)-mediated adhesion to fibronectin.

Authors:  S P Neeley; K J Hamann; T L Dowling; K T McAllister; S R White; A R Leff
Journal:  Am J Respir Cell Mol Biol       Date:  1994-08       Impact factor: 6.914

7.  Adhesion to fibronectin primes eosinophils via alpha 4 beta 1 (VLA-4).

Authors:  A R Anwar; G M Walsh; O Cromwell; A B Kay; A J Wardlaw
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

8.  Dissociation between increased surface expression of gp165/95 and homotypic neutrophil aggregation.

Authors:  J P Buyon; S B Abramson; M R Philips; S G Slade; G D Ross; G Weissmann; R J Winchester
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

9.  Organization, regulatory sequences, and alternatively spliced transcripts of the mucosal addressin cell adhesion molecule-1 (MAdCAM-1) gene.

Authors:  S O Sampaio; X Li; M Takeuchi; C Mei; U Francke; E C Butcher; M J Briskin
Journal:  J Immunol       Date:  1995-09-01       Impact factor: 5.422

10.  Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes.

Authors:  D J Erle; M J Briskin; E C Butcher; A Garcia-Pardo; A I Lazarovits; M Tidswell
Journal:  J Immunol       Date:  1994-07-15       Impact factor: 5.422

View more
  18 in total

Review 1.  Integrin signalling and function in immune cells.

Authors:  Yanbo Zhang; Hongyan Wang
Journal:  Immunology       Date:  2012-04       Impact factor: 7.397

2.  EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling.

Authors:  Martin Kohan; Andres F Muro; Eric S White; Neville Berkman
Journal:  FASEB J       Date:  2010-07-19       Impact factor: 5.191

3.  A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats.

Authors:  Julio Cortijo; María-Jesús Sanz; Arantxa Iranzo; José Luis Montesinos; Yafa Naim Abu Nabah; José Alfón; Luis A Gómez; Manuel Merlos; Esteban J Morcillo
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

4.  Lactoferrin regulates an axis involving CD11b and CD49d integrins and the chemokines MIP-1α and MCP-1 in GM-CSF-treated human primary eosinophils.

Authors:  Colleen S Curran; Paul J Bertics
Journal:  J Interferon Cytokine Res       Date:  2012-06-25       Impact factor: 2.607

5.  The C-C chemokine receptor CCR3 participates in stimulation of eosinophil arrest on inflammatory endothelium in shear flow.

Authors:  J Kitayama; C R Mackay; P D Ponath; T A Springer
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

Review 6.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

7.  Dissection of the hyperadhesive phenotype of airway eosinophils in asthma.

Authors:  Steven R Barthel; Nizar N Jarjour; Deane F Mosher; Mats W Johansson
Journal:  Am J Respir Cell Mol Biol       Date:  2006-04-06       Impact factor: 6.914

8.  Aberrant activation of integrin alpha4beta7 suppresses lymphocyte migration to the gut.

Authors:  Eun Jeong Park; J Rodrigo Mora; Christopher V Carman; JianFeng Chen; Yoshiteru Sasaki; Guiying Cheng; Ulrich H von Andrian; Motomu Shimaoka
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 9.  Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma.

Authors:  Steven R Barthel; Mats W Johansson; Dawn M McNamee; Deane F Mosher
Journal:  J Leukoc Biol       Date:  2007-10-10       Impact factor: 4.962

10.  Identification of the active site in the heparin II domain of fibronectin that increases outflow facility in cultured monkey anterior segments.

Authors:  Jose M Gonzalez; Yujie Hu; B'Ann T Gabelt; Paul L Kaufman; Donna M Peters
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-29       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.